electroCore Expands Intellectual Property Portfolio
January 09, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation
January 03, 2024 09:04 ET
|
Brain & Behavior Research Foundation
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
January 02, 2024 08:00 ET
|
Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
November 11, 2023 01:46 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
Eight virtual conference sessions explore psychedelic research for Veterans including trauma support, federal backing, and a pilot study on Ibogaine
Pediatric PTSD: Neurobiology and Treatment - A Free Webinar from the Brain & Behavior Research Foundation
November 09, 2023 10:28 ET
|
Brain & Behavior Research Foundation
New York, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Pediatric PTSD: Neurobiology and Treatment” on Tuesday, November 14, 2023,...
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET
|
PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 08, 2023 08:11 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
Mydecine Provides Q4 2023 Business Update
October 26, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
Mydecine is pleased to address its shareholders and provide a general update on the company's progress.